SCHEMBL4291348

SCHEMBL4291348

Cc1ccccc1-c1c(-c2ccc(F)c(C#N)c2)nnn1CC1CCOCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.61
MAP4K4 O95819 2/20 0.38
PRKACA P17612 2/20 0.38
GSK3B P49841 2/20 0.38
CLK4 Q9HAZ1 2/20 0.38
PIM1 P11309 1/20 0.38
CDK2 P24941 1/20 0.38
HIPK2 Q9H2X6 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
MET P08581 3/20 0.38
LRRK2 Q5S007 2/20 0.38
TBK1 Q9UHD2 2/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
PRKD3 O94806 1/20 0.38
PAK4 O96013 1/20 0.38
CSF1R P07333 1/20 0.38
LTK P29376 1/20 0.38
MAPK8 P45983 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3665208 0.80 CDC7 (0.58) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL4291361 0.77 CDC7 (0.71) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL4289776 0.74 CDC7 (0.57) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3637386 0.67 CDC7 (0.55) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3666291 0.67 CDC7 (0.53) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3673146 0.67 CDC7 (0.49) CDC7SIGMAR1GRM2TDO2BRD4
SCHEMBL3665335 0.66 ROCK2 (0.58) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL4289119 0.66 CDC7 (0.58) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL4289379 0.66 CDC7 (0.58) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL4295841 0.65 CDC7 (0.59) CDC7MAP4K4PRKACAGSK3BCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885MAP4K4 51/4885PRKACA 178/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885MAP4K4 51/4885PRKACA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.